Department of Gynecology and Obstetrics, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, P.R. China
Department of Gynecology and Obstetrics, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, P.R. China.
Biosci Rep. 2019 Apr 2;39(4). doi: 10.1042/BSR20182186. Print 2019 Apr 30.
The long noncoding RNA small nucleolar RNA host gene 20 (SNHG20) has been demonstrated to play a crucial role in cancer progression. However, the functions of SNHG20 in epithelial ovarian cancer (EOC) are not well established. The aim of the present study was to investigate SNHG20 clinical significance and its underlying mechanism in proliferation and metastasis in EOC. The expression level of SNHG20 was identified via hybridization (ISH) and quantitative RT-PCR (qRT-PCR). The proliferative and metastatic capacities by silencing SNHG20 expression in A2780 and CAOV-3 cells were measured by cell counting kit-8 (CCK-8) and transwell assays. The molecular mRNA and protein expressions were examined using qRT-PCR, Western blot, and double immunofluorescent staining. SNHG20 expression was markedly higher in serous EOC tissues than that in adjacent tissues and closely correlated with histological grade and lymph node (LN) status. Patients with high SNHG20 showed a shorter overall survival (OS) and SNHG20 was an independent risk factor for the prognosis of serous EOC. Knockdown of SNHG20 remarkably inhibited EOC cell proliferation, migration, and invasion, which was associated with dysregulation of P21, Cyclin D1, E-cadherin, and Vimentin. These results suggest that SNHG20 may serve as an independent prognostic predictor and function as a noncoding oncogene in EOC progression, which might be a possible novel diagnostic marker and treatment target.
长链非编码 RNA 小核仁 RNA 宿主基因 20(SNHG20)已被证明在癌症进展中发挥关键作用。然而,SNHG20 在卵巢上皮性癌(EOC)中的功能尚未得到充分证实。本研究旨在探讨 SNHG20 在 EOC 增殖和转移中的临床意义及其潜在机制。通过杂交(ISH)和定量 RT-PCR(qRT-PCR)确定 SNHG20 的表达水平。通过沉默 A2780 和 CAOV-3 细胞中的 SNHG20 表达来测量增殖和转移能力,通过细胞计数试剂盒-8(CCK-8)和 Transwell 测定。使用 qRT-PCR、Western blot 和双重免疫荧光染色检测分子 mRNA 和蛋白表达。SNHG20 在浆液性 EOC 组织中的表达明显高于相邻组织,并且与组织学分级和淋巴结(LN)状态密切相关。SNHG20 高表达的患者总生存期(OS)较短,SNHG20 是浆液性 EOC 预后的独立危险因素。SNHG20 的敲低显著抑制了 EOC 细胞的增殖、迁移和侵袭,这与 P21、Cyclin D1、E-钙黏蛋白和波形蛋白的失调有关。这些结果表明,SNHG20 可能作为独立的预后预测因子,并作为 EOC 进展中的非编码癌基因发挥作用,可能是一种潜在的新型诊断标志物和治疗靶点。